Antifungal drug resistance: Do molecular methods provide a way forward?

Current Opinion in Infectious Diseases

Volumn 22, Issue 6, 2009, Pages 568-573

  Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Antifungal drug resistance; Fungal infections; Molecular diagnostics

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS; BROTH DILUTION; CANDIDA; CANDIDIASIS; DISK DIFFUSION; EARLY DIAGNOSIS; FUNGAL COLONIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOSES; POLYMERASE CHAIN REACTION;

EID: 70350536660     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283321ce5     Document Type: Review

References (79)

1. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy 2004; 24:4S-28S; quiz 29S-32S.
2. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133-163.
4. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hema-topoietic stem cell transplant recipients. Mycopathologia 2006; 162:1-15.
5. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67:1567-1601.
6. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531-540.
7. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139:519-531.
8. Marr KA. Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol 2008; 46:293-302.
9. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007; 67:1803-1812.
10. Stevens DA. Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002; 49 (Suppl 1):11-19.
11. Chamilos G, Kontoyiannis DP. Defining the diagnosis of invasive aspergillosis. Med Mycol 2006; 44 (Suppl):163-172.
12. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study. Clin Infect Dis 2006; 43:25-31.
13. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-3645.
14. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007; 78:275-282.
15. Ruping MJ, Vehreschild JJ, Cornely OA. Antifungal treatment strategies in high risk patients. Mycoses 2008; 51 (Suppl 2):46-51.
16. Thursky KA, Playford EG, Seymour JF, et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008; 38:496-520.
17. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360.
18. Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Huntingt) 2004; 18:9-14.
19. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45:1735-1745.
20. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 (Suppl 1):11-23.
21. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356:1481-1483
22. Snelders E, van derLee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PloS Med 2008; 5:e219
23. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15:1068-1076.
24. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 2003; 6:197-218.
25. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142-1151.
26. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003; 12:1313-1333.
27. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006; 63:1693-1703. (Pubitemid 44413505)
28. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46:3001-3012.
29. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150-156.
30. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008; 52:2263-2265.
31. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resis-tant Candida tropicalis strains causing breakthrough fungemia in patients at high riskfor hematologic malignancies. Antimicrob Agents Chemother 2008; 52:4181-4183.
32. Arendrup MC, Garcia-Effron G, Buzina W, et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2008; 53:1185-1193.
33. Kahn JN, Garcia-Effron G, Hsu MJ, et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51:1876-1878.
34. Miller CD, Lomaestro BW, ParkS, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006; 26:877-880.
35. Laverdiere M, Lalonde RG, Baril JG, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57:705-708
36. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. 2nd ed. Approved Standard M27-A2. Wayne, PA, USA; 2002.
37. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46:2620-2629.
38. Reiss E, Obayashi T, Orle K, Yoshida M, et al. Nonculture based diagnostic tests for mycotic infections. Med Mycol 2000; 38 (Suppl 1):147-159.
39. Zhao Y, Park S, Kreiswirth BN, et al. Rapid real-time nucleic acid sequence-based amplification-molecular beacon platform to detect fungal and bacterial bloodstream infections. J Clin Microbiol 2009; 47:2067-2078.
40. Elie CM, Lott TJ, Reiss E, Morrison CJ. Rapid identification of Candida species with species-specific DNA probes. J Clin Microbiol 1998; 36: 3260-3265.
41. Perlin DS, Zhao Y. Molecular diagnostic platforms for detecting Aspergillus. Med Mycol 2009; 47 (Suppl 1):S223-232.
42. Reiss E, Morrison CJ. Nonculture methods for diagnosis of disseminated candidiasis. Clin Microbiol Rev 1993; 6:311-323.
43. Loeffler J, Hebart H, Cox P, et al. Nucleic acid sequence-based amplification of Aspergillus RNA in blood samples. J Clin Microbiol 2001; 39:1626-1629.
44. Perlin DS, Park S. Rapid identification of fungal pathogens: molecular approaches for a new millennium. Rev Med Microbiol 2001; 12 (suppl): S13-S20.
45. Alexander BD. Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl Infect Dis 2002; 4 (Suppl 3):32-37.
46. De Marco D, Perotti M, Ossi CM, et al. Development and validation of a molecular method for the diagnosis of medically important fungal infections. New Microbiol 2007; 30:308-312.
47. Loeffler J, Dorn C, Hebart H, et al. Development and evaluation of the nuclisens basic kit NASBA for the detection of RNA from Candida species frequently resistant to antifungal drugs. Diagn Microbiol Infect Dis 2003; 45:217-220.
48. Weile J, Knabbe C. Current applications and future trends of molecular diagnostics in clinical bacteriology. Anal Bioanal Chem 2009; 394:731-742.
49. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39:3254-3259.
50. Steinbach WJ, Perfect JR, Schell WA, et al. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48:3217-3225.
51. Perlin DS, Balashov S, Park S. Multiplex detection of mutations. Methods Mol Biol 2008; 429:23-31.
52. Perlin DS. Application of real-time PCR to the diagnosis of invasive fungal infections. In real-time PCR: current technology and applications. In: Logan J, Edwards K, Saunders N, editors. Norfolk, UK: Caister Academic Press; 2009. pp. 221-234.
53. Sanglard D, Ischer F, Parkinson T, et al. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003; 47:2404-2412.
54. Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145 (Pt 10):2701-2713.
55. Wiederhold NP, Grabinski JL, Garcia-Effron G, et al. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 2008; 52:4145-4148.
56. Park S, Perlin DS. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist 2005; 11:232-238.
57. Loeffler J, Hagmeyer L, Hebart H, et al. Rapid detection of point mutations by fluorescence resonance energy transfer and probe melting curves in Candida species. Clin Chem 2000; 46:631-635.
58. Yan L, Zhang J, Li M, et al. DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain. Acta Biochim Biophys Sin 2008; 40:1048-1060.
59. White TC, Holleman S, Dy F, et al. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46:1704-1713.
60. Gygax SE, Vermitsky JP, Chadwick SG, et al. Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay. Antimicrob Agents Chemother 2008; 52:3424-3426.
61. Kofla G, Ruhnke M. Development of a new real-time TaqMan PCR assay for quantitative analyses of Candida albicans resistance genes expression. J Microbiol Methods 2007; 68:178-183.
62. Coste AT, Karababa M, Ischer F, et al. TAC1, transcriptional activator of CDR genes,isanew transcription factor involvedintheregulationofCandida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3:1639-1652.
63. Coste A, Turner V, Ischer F, et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 2006; 172:2139-2156.
64. Coste A, Selmecki A, Forche A, et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 2007; 6:1889-1904.
65. Selmecki A, Gerami-Nejad M, Paulson C, et al. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 2008; 68:624-641.
66. Vermitsky JP, Edlind TD. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother 2004; 48:3773-3781.
67. Vermitsky JP, Earhart KD, Smith WL, et al. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Mol Microbiol 2006; 61:704-722.
68. Tsai HF, Krol AA, Sarti KE, Bennett JE. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother 2006; 50:1384-1392.
69. Silver PM, Oliver BG, White TC. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot Cell 2004; 3: 1391-1397.
70. Dunkel N, Liu TT, Barker KS, et al. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell 2008; 7:1180-1190.
71. Balashov SV, Gardiner R, Park S, Perlin DS. Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole. J Clin Microbiol 2005; 43:214-222.
72. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, et al. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol 2008;46:1200-1206.
73. Trama JP, Mordechai E, Adelson ME. Detection of Aspergillus fumigatus and a mutation that confers reduced susceptibility to itraconazole and posaco-nazole by real-time PCR and pyrosequencing. J Clin Microbiol 2005; 43:906-908.
74. Tuohy MJ, Reja V, Park S, et al. The use of high-resolution melt on the rotor-gene 6000 to characterize codon 54 of the cyp51A gene of Aspergillus fumigatus. In Abstract C-217 ASM 2008, Boston, MA.
75. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10:121-130.
76. Garcia-Effron G, Lee S, Park S, et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-{beta}-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009 [Epub ahead of print].
77. Garcia-Effron G, ParkS, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53:112-122.
78. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1 p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-3273.
79. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50:2058-2063.